Generic Elavil ( Amitriptyline )

Buy Generic Elavil (Amitriptyline) without prescription in Canada

In our Canadian pharmacy, you can buy Elavil (Amitriptyline) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Elavil (amitriptyline hydrochloride) is a tricyclic antidepressant (TCA) used primarily to treat major depressive disorder, and at lower doses, it is also widely prescribed for the management of chronic neuropathic pain, migraine prophylaxis, and tension‑type headaches. It works by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine into presynaptic nerve terminals, which increases their availability in the synaptic cleft and enhances mood‑regulating neurotransmission. This action helps relieve depression, anxiety, and certain types of persistent pain.

Usual adult dose: For depression, treatment is usually started at a low dose of 25 mg to 50 mg taken at bedtime, which may be gradually increased every 3 to 7 days to a total daily dose of 150 mg to 200 mg. The maximum recommended dose is 300 mg daily. For neuropathic pain, migraine prophylaxis, or insomnia, lower doses of 10 mg to 25 mg taken once daily at bedtime are often effective. Doses may be divided if daytime sedation occurs, but a single bedtime dose is preferred for most patients.

Dosage form: Oral tablets available in 10 mg, 25 mg, and 50 mg strengths.

Onset of action: Some improvement in sleep, energy, or appetite may occur within the first 1 to 2 weeks of treatment. However, the full antidepressant effect typically requires 4 to 6 weeks of continuous therapy. Pain relief may begin within a few days to a week when used for neuropathic conditions.

Duration of action: The elimination half‑life of amitriptyline is approximately 10 to 28 hours, with its active metabolite nortriptyline having a half‑life of 18 to 44 hours. This supports once‑daily dosing at bedtime for most patients.

Alcohol recommendation: Alcohol consumption should be strictly avoided during treatment with Elavil. Alcohol can potentiate the central nervous system depressant effects of amitriptyline, leading to excessive sedation, impaired coordination, and an increased risk of respiratory depression. It may also worsen depression and anxiety.

Most common side effects: Dry mouth, drowsiness, dizziness, blurred vision, constipation, difficulty urinating, and weight gain. These anticholinergic and sedative effects are often dose‑dependent and may diminish over time or with dose adjustment.

Would you like to try Elavil (Amitriptyline) without a prescription?

General Information about Elavil (Amitriptyline)

• INN (International Nonproprietary Name): Amitriptyline (as amitriptyline hydrochloride).
• Brand names available in Canada: Historically, the brand names Elavil® and Levate® were marketed in Canada, but both are now cancelled post‑market. Generic formulations are widely available and include APO‑Amitriptyline (Apotex Inc.), TEVA‑Amitriptyline (Teva Canada Limited), PMS‑Amitriptyline (Pharmascience Inc.), Sandoz Amitriptyline (Sandoz Canada Inc.), JAMP‑Amitriptyline (JAMP Pharma Corporation), and others.
• ATC code: N06AA09.
• Dosage forms and strengths: Oral tablets: 10 mg, 25 mg, 50 mg, and 75 mg (as amitriptyline hydrochloride). An injectable solution (10 mg/mL) is also available in some settings.
• Manufacturers in Canada: Apotex Inc., Teva Canada Limited, Pharmascience Inc., Sandoz Canada Inc., JAMP Pharma Corporation, and other generic pharmaceutical companies. Historically, Merck Sharp & Dohme Canada Ltd. (Elavil).
• Registration status in Canada: Approved by Health Canada. Multiple generic formulations are currently marketed and available by prescription.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act.

Mechanism of Action and Pharmacology

Amitriptyline is a tertiary amine tricyclic antidepressant with a broad pharmacological profile. Its primary mechanism of action is the inhibition of the presynaptic reuptake of the monoamine neurotransmitters serotonin (5‑HT) and norepinephrine (NE). It is a potent inhibitor of the serotonin transporter (SERT) and a somewhat less potent inhibitor of the norepinephrine transporter (NET). By blocking these transporters, amitriptyline increases the synaptic availability of these neurotransmitters, thereby enhancing monoaminergic neurotransmission in brain regions associated with mood regulation. This action is thought to underlie its antidepressant and analgesic effects. In the central nervous system, amitriptyline also blocks sodium channels, which contributes to its efficacy in neuropathic pain.

In addition to monoamine reuptake inhibition, amitriptyline possesses a high affinity for histamine H₁ receptors (causing significant sedation and weight gain), muscarinic cholinergic receptors (causing dry mouth, blurred vision, constipation, urinary retention, and memory difficulties), and alpha‑1 adrenergic receptors (causing orthostatic hypotension). Among the TCAs, amitriptyline is one of the most sedating and anticholinergic. Amitriptyline is metabolised in the liver primarily by cytochrome P450 isoenzymes CYP2C19 and CYP2D6 to its active metabolite, nortriptyline (a secondary amine TCA with a predominantly noradrenergic profile). The elimination half‑life of amitriptyline is 10 to 28 hours, and that of nortriptyline is 18 to 44 hours, allowing once‑daily dosing. Therapeutic drug monitoring is recommended, with a combined target range of 100 to 250 ng/mL for amitriptyline and nortriptyline together.

Indications

• Major Depressive Disorder (MDD): For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states.
• Neuropathic Pain: Off‑label, amitriptyline is widely used as a first‑line agent for the management of chronic neuropathic pain, including painful diabetic neuropathy, postherpetic neuralgia, and fibromyalgia.
• Migraine Prophylaxis: Off‑label, it is a first‑line prophylactic agent for the prevention of migraine headaches and tension‑type headaches.
• Other Off‑label Uses: Insomnia (especially when associated with pain or depression), generalised anxiety disorder, panic disorder, post‑traumatic stress disorder (PTSD), irritable bowel syndrome (IBS), and interstitial cystitis.
• It is not approved for the treatment of bipolar depression due to the risk of precipitating a manic episode. Safety and efficacy in paediatric patients for depression have not been established, though it is used off‑label for enuresis and neuropathic pain under specialist guidance.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: There are no adequate and well‑controlled studies in pregnant women. Amitriptyline should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the foetus. Neonates exposed late in the third trimester may develop withdrawal symptoms.
• Breastfeeding: Amitriptyline and its metabolite are excreted in breast milk in small amounts. Sedation has been reported in some nursing infants. A decision should be made whether to discontinue breastfeeding or to discontinue the drug.
• Paediatrics: Safety and efficacy for depression have not been established in children. Use in children is reserved for specific off‑label indications under specialist care. Antidepressants increase the risk of suicidal thoughts in children and young adults.
• Elderly: Elderly patients are highly sensitive to anticholinergic, sedative, and hypotensive effects. Amitriptyline is included in the Beers Criteria as a potentially inappropriate medication for older adults. If used, start with the lowest possible dose (e.g., 10 mg at bedtime) and monitor closely for confusion, falls, urinary retention, and cardiac arrhythmias.
• Hepatic impairment: Use with caution; lower doses are recommended as metabolism may be reduced.
• Renal impairment: No dose adjustment is usually needed, but caution is advised due to potential increased sensitivity to side effects.
• Cardiovascular disease: Amitriptyline can cause QT prolongation, orthostatic hypotension, and tachycardia. It is contraindicated during the acute recovery phase after a myocardial infarction. A baseline ECG is recommended in patients with cardiac risk factors.
• Angle‑closure glaucoma: Can cause pupillary dilatation, triggering an acute attack in susceptible individuals.
• Bipolar disorder: Screen for bipolar disorder; TCAs carry a high risk of precipitating mania.
• Seizure disorders: May lower the seizure threshold; use with caution in patients with epilepsy.
• Suicidality: All antidepressants carry a warning for increased risk of suicidal thinking and behaviour in children, adolescents, and young adults.
• Serotonin syndrome: A potentially life‑threatening condition may occur, particularly when combined with other serotonergic drugs.

Driving and alcohol

Elavil causes significant drowsiness, dizziness, and blurred vision, and can severely impair the mental alertness and physical coordination required for driving or operating machinery. Patients should not engage in such activities until they have determined how the medication affects them. Alcohol must be strictly avoided, as it greatly increases the sedative and psychomotor‑impairing effects of amitriptyline and may lead to fatal respiratory depression.

Dosage Instructions

• Major Depressive Disorder (Adults): Start with 25 mg to 50 mg at bedtime. The dose may be increased by 25 mg to 50 mg every 3 to 7 days as tolerated, to a target range of 150 mg to 200 mg daily. The maximum dose is 300 mg per day. Doses above 100 mg should be given in divided doses or as a single dose at bedtime if tolerated.
• Neuropathic Pain or Migraine Prophylaxis (Adults): Initiate at a low dose of 10 mg to 25 mg at bedtime. The dose may be titrated up by 10 mg to 25 mg weekly to a typical effective range of 25 mg to 100 mg at bedtime.
• Elderly or Debilitated Patients: Start with 10 mg at bedtime. Titrate slowly, often not exceeding 50 mg to 100 mg daily.
• Administration: Take the tablet with a full glass of water. It is best taken at bedtime to reduce the impact of daytime drowsiness. Taking it with food may reduce stomach upset.
• Missed dose: If a dose is missed, take it as soon as remembered on the same day. If it is close to the time of the next dose, skip the missed dose. Do not double the dose.
• Discontinuation: The dose must be gradually tapered under medical supervision to avoid withdrawal symptoms such as nausea, headache, irritability, and insomnia.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Dry mouth, drowsiness, dizziness, weight gain, constipation, and blurred vision.
• Common side effects (1‑10%): Nausea, increased appetite, fatigue, weakness, confusion (especially in the elderly), urinary retention, sexual dysfunction, and excessive sweating.
• Serious adverse reactions: Cardiac arrhythmias (including QT prolongation and torsades de pointes), orthostatic hypotension and syncope, serotonin syndrome, seizures, neuroleptic malignant syndrome, agranulocytosis, and acute hepatitis. An overdose of amitriptyline is frequently fatal due to cardiac toxicity.
• Contraindications: Hypersensitivity to amitriptyline or any excipient. Concomitant use with monoamine oxidase inhibitors (MAOIs), including linezolid and intravenous methylene blue, or within 14 days of discontinuing an MAOI. Acute recovery phase following myocardial infarction. Untreated narrow‑angle glaucoma. Co‑administration with cisapride is contraindicated due to the risk of serious cardiac arrhythmias.

Drug Interactions

• Monoamine oxidase inhibitors (MAOIs): Contraindicated; risk of serotonin syndrome and hypertensive crisis. A 14‑day washout is required.
• Serotonergic drugs: SSRIs, SNRIs, triptans, fentanyl, lithium, tramadol, and others increase the risk of serotonin syndrome.
• CYP2D6 and CYP2C19 inhibitors: Fluoxetine, paroxetine, bupropion, and others can increase amitriptyline levels, requiring dose reduction.
• CNS depressants: Alcohol, benzodiazepines, opioids, and antihistamines add to sedation and psychomotor impairment.
• Anticholinergic agents: Additive side effects (dry mouth, constipation, urinary retention) when combined with other anticholinergic drugs.
• QT‑prolonging drugs: Increased risk of cardiac arrhythmias when used with certain antiarrhythmics, antibiotics, and antipsychotics.
• Antihypertensives: Amitriptyline may antagonise the effects of certain blood‑pressure‑lowering drugs.

Practical Advice

• Administration: Take the medication exactly as prescribed, preferably at bedtime. Swallow the tablet whole with water. Rising slowly from a sitting or lying position helps prevent dizziness from orthostatic hypotension.
• Monitoring: Regular follow‑up with your doctor is essential. This includes monitoring for therapeutic response, emergence of suicidal thoughts, cardiac function (ECG if symptoms develop), and periodic checks of liver function and blood counts if on long‑term therapy. Weight should also be monitored.
• Storage: Store at room temperature (15‑30 °C) in a tightly closed container, protected from light and moisture. Keep out of reach of children, as even a small overdose can be fatal.
• Lifestyle: To manage dry mouth, sip water frequently or chew sugarless gum. Maintain adequate fluid and fibre intake to prevent constipation. Avoid prolonged sun exposure and use sunscreen. Do not drink alcohol. Amitriptyline can make you drowsy; do not drive until you know its full effect.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet.

Alternative Medications

• Selective serotonin reuptake inhibitors (SSRIs): Sertraline, escitalopram, and fluoxetine are first‑line antidepressants with fewer anticholinergic side effects and are far safer in overdose.
• Serotonin‑norepinephrine reuptake inhibitors (SNRIs): Duloxetine and venlafaxine are first‑line agents for both depression and neuropathic pain, with a better tolerability profile than amitriptyline.
• Other TCAs: Nortriptyline is the active metabolite of amitriptyline and is often better tolerated by elderly patients, as it causes less sedation and fewer anticholinergic effects. Desipramine is another alternative with a predominantly noradrenergic profile.
• Other analgesics for neuropathic pain: Gabapentin and pregabalin are first‑line anticonvulsants for neuropathic pain and do not have the anticholinergic or cardiac toxicity of amitriptyline.
• Other migraine prophylactics: Propranolol, topiramate, and candesartan are first‑line options for migraine prevention.
• Non‑pharmacological approaches: Cognitive behavioural therapy (CBT), interpersonal therapy (IPT), and behavioural activation are evidence‑based psychotherapies for depression. For pain, physiotherapy, acupuncture, and relaxation techniques can be helpful.

Clinical Efficacy

Amitriptyline is one of the oldest and most extensively studied antidepressants. In numerous placebo‑controlled trials for major depressive disorder, it has consistently demonstrated superior efficacy to placebo, achieving response rates of approximately 60‑70%. It is considered one of the most effective antidepressants, with a 2024 network meta‑analysis of over 450 randomised controlled trials finding that amitriptyline was one of the few agents with a statistically significant higher response rate compared with placebo and several other active comparators. For neuropathic pain, a Cochrane systematic review of 21 studies concluded that amitriptyline is effective at achieving a 50% or greater reduction in pain, with a number needed to treat (NNT) of approximately 4. It remains a first‑line therapy in guidelines from the Canadian Pain Society and the European Federation of Neurological Societies. For migraine prophylaxis, amitriptyline has been shown to reduce migraine frequency by 50% or more in a significant proportion of patients, making it a cornerstone of prophylactic treatment. The clinical utility of amitriptyline is often limited by its anticholinergic and sedative side effects, and its danger in overdose, but it remains a valuable second‑ or third‑line agent for depression and a first‑line agent for many pain conditions.

Important:

Elavil (amitriptyline) is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It carries a boxed warning for an increased risk of suicidal thinking and behaviour in children, adolescents, and young adults. All patients, regardless of age, should be closely monitored for clinical worsening, suicidality, or unusual changes in behaviour. This medication can cause significant drowsiness and dizziness; do not drive or operate machinery until you know how it affects you. Alcohol must be strictly avoided, as the combination can lead to severe respiratory depression, coma, and death. Amitriptyline is extremely dangerous in overdose, and even a small excess can be fatal, particularly in children; always store it securely. Do not stop this medication abruptly. If you experience a severe allergic reaction, cardiac symptoms (such as fainting or an irregular heartbeat), or signs of serotonin syndrome (agitation, confusion, high fever, muscle rigidity), seek emergency medical attention immediately. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Elavil - Shipping across Canada